Advanced Decellularized Dermis
Dermacell is a decellularized regenerative human tissue matrix allograft processed using proprietary Matracell® technology from LifeNet Health®.
Adequate blood supply is critical for successful use of decellularized regenerative human tissue matrix allografts.
LifeNet Health® has the longest running American Association of Tissue Banks certification and is also the world’s largest full service provider of organs, tissues, and cells. LifeNet Health has more than 30 years of experience in tissue regeneration including expertise in advanced sterilization techniques for biologic matrices
Sterility assurance level (SAL) 10-6
Ready To Use (RTU)
No rinsing required.
Decellularized using Matracell
A proprietary and patented technology that removes at least 97% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.
Introducing the No Red Breast Guarantee
Recent findings have demonstrated that the use of Dermacell Acellular Dermal Matrix in immediate breast reconstruction has advantages over AlloDerm Ready-To-Use (RTU), including a significantly lower incidence of red breast syndrome. (0% vs 26%, p=0.0001).1
Based on this as well as other compelling research, we are proud to officially introduce the No Red Breast Guarantee. In the event that red breast syndrome occurs in a patient within 40 days of the original procedure date, NOVADAQ will grant a credit for the tissue provided that proof of red breast syndrome can be documented and no clinical indicators of an underlying infection were present.
For more information on Dermacell ADM and/or the No Red Breast Guarantee, please contact us.
1. Pittman TA, Fan KL, Knapp A, Frantz S, Spear SL. Comparison of Different Acellular Dermal Matrix (ADM) in Breast Reconstruction: The 50/50 Study. Journal of Plastic and Reconstructive Surgery (2017)
Dermacell is sterile – sterility assurance level (SAL) 10-6 and ready to use – no rinsing required.
Dermacell is decellularized using Matracell, a proprietary and patented technology that removes at least 97% of donor DNA without compromising the desired biomechanical structure or biochemical properties for its intended use.
After being rendered acellular, Dermacell undergoes a terminal sterilization step to ensure a Sterility Assurance Level (SAL) of 10-6
Low-dose gamma irradiation performed at ultra-low temperatures is used to reach surgical device-grade sterility, which lowers the probability of an active organism in the graft to 1 in 1,000,000 – lower than 10-3 or, a 1 in a 1,000 chance
- All of this is achieved without compromising the desired biomechanical structures or biochemical properties (i.e. cross-linking) of the biologic matrix
In implant breast reconstruction, surgeons utilize decellularized tissue matrices, such as Dermacell to do the following:
- Help to define the contour and shape of the new breast
- Create a biologic interface between mastectomy skin flaps potentially reducing the risk of infection
- Provide supplemental reinforcement to the soft tissue
Peer-reviewed, non-industry funded studies including Evaluation of Host Tissue Integration, Revascularization, and Cellular Infiltration within Various Dermal Substrates reported that Dermacell was associated with the furthest cell infiltration and migration of all acellular dermal matrices studied.1
- Dermacell: >97% of donor DNA removed 2
A recent internal lab study found
- AlloDerm RTU had more than 50 times the residual donor DNA content than Dermacell*
- GraftJacket has more than 150 times the residual donor DNA content than Dermacell*
- Dermacell had the highest degree of cellular infiltration/migration – 184% more than AlloDerm 1
Clinical data suggests that Dermacell induces less inflammation and myofibroblasts, helps to reduce seroma and infection rates, and is safe and effective in a range of patient types including patients receiving post-operative chemotherapy and post-operative radiation.
- Hanna et al. | Annals of Plastic Surgery (In Submission) 3
- Matracell processed, sterilized acellular dermal matrix in implant-based breast reconstruction: clinical and histologic outcomes
- Dermacell may have an advantage over AlloDerm in terms of seroma and infection rates in breast reconstruction. Histologic analysis confirms Dermacell “to have desirable properties of low immunogenicity, low levels of fibrosis, and minor inflammation.”
- Key Results:
- Lower rates of infection and seroma in the Dermacell group, although not statistically significant.
- No difference between groups in regard to wound separation.
- Key Results: